Number of the records: 1
Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: The randomized, controlled EMPA-VISION trial
Title Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: The randomized, controlled EMPA-VISION trial. textový dokument (print) Author Hundertmark M. Co-authors Adler A. Antoniades C. Coleman R. Griffin J.L. Holman R. Lamlum H. Lee J. Massey D. Miller J.J. Milton J. Monga S. Mózes F.E. Nazeer A. Raman B. Rider O. Rodgers C.T. Valkovič Ladislav 1986 SAVMER - Ústav merania SAV SCOPUS RID ORCID Wicks E. Mahmod M. Neubauer S. Source document Circulation. Vol. 147, no. 22 (2023), p. 1654-1669 Language eng - English Country US - United States of America Document kind rozpis článkov z periodík (rbx) Citations SU, S. - JI, X. - LI, T. - TENG, Y. - WANG, B.F. - HAN, X.W. - ZHAO, M.J. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. In FRONTIERS IN CARDIOVASCULAR MEDICINE. ISSN 2297-055X, DEC 6 2023, vol. 10. Dostupné na: https://doi.org/10.3389/fcvm.2023.1291450. RODRIGUES, E.A. - ROSA, C.M. - CAMPOS, D.H.S. - DAMATTO, F.C. - MURATA, G.M. - SOUZA, L.M. - PAGAN, L.U. - GATTO, M. - BROSLER, J.Y. - SOUZA, H.O.A. - MARTINS, M.M. - BASTOS, L.M. - TANNI, S.E. - OKOSHI, K. - OKOSHI, M.P. The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats. In DIABETOLOGY & METABOLIC SYNDROME. OCT 31 2023, vol. 15, no. 1. Dostupné na: https://doi.org/10.1186/s13098-023-01196-6. CARLUCCIO, E. - BIAGIOLI, P. - REBOLDI, G. - MENGONI, A. - LAUCIELLO, R. - ZUCHI, C. - D'ADDARIO, S. - BARDELLI, G. - AMBROSIO, G. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. In CARDIOVASCULAR DIABETOLOGY. SEP 2 2023, vol. 22, no. 1. Dostupné na: https://doi.org/10.1186/s12933-023-01970-w. GOLLEDGE, J. Can a genetic mutation associated with glycosuria teach us about the action of sodium-glucose cotransporter-2 inhibitors?. In CARDIOVASCULAR RESEARCH. ISSN 0008-6363, 2023 NOV 15 2023, vol. 119, no. 14, p. 2385-2386. Dostupné na: https://doi.org/10.1093/cvr/cvad142. LI, A.L. - LIAN, L. - CHEN, X.N. - CAI, W.H. - FAN, X.B. - FAN, Y.J. - LI, T.T. - XIE, Y.Y. - ZHANG, J.P. The role of mitochondria in myocardial damage caused by energy metabolism disorders: From mechanisms to therapeutics. In FREE RADICAL BIOLOGY AND MEDICINE. ISSN 0891-5849, 2023 NOV 1 2023, vol. 208, p. 236-251. Dostupné na: https://doi.org/10.1016/j.freeradbiomed.2023.08.009. ABDULLAH, A. Targeting metabolism to treat heart failure. In CONDITIONING MEDICINE. ISSN 2577-3240, 2023, vol. 6, no. 2, p. 54-64. Dostupné na: http://www.conditionmed.org/Data/View/15028. GAO, S. - LIU, X.P. - LI, T.T. - CHEN, L. - FENG, Y.P. - WANG, Y.K. - YIN, Y.J. - LITTLE, P.J. - WU, X.Q. - XU, S.W. - JIANG, X.D. Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery. In ACTA PHARMACOLOGICA SINICA. ISSN 1671-4083, JAN 2024, vol. 45, no. 1, p. 23-35. Dostupné na: https://doi.org/10.1038/s41401-023-01152-0. WEI, J.F. - DUAN, X.F. - CHEN, J.Y. - ZHANG, D.W. - XU, J.D. - ZHUANG, J. - WANG, S. Metabolic adaptations in pressure overload hypertrophic heart. In HEART FAILURE REVIEWS. ISSN 1382-4147, JAN 2024, vol. 29, no. 1, p. 95-111. Dostupné na: https://doi.org/10.1007/s10741-023-10353-y. CERSOSIMO, A. - DRERA, A. - ADAMO, M. - METRA, M. - VIZZARDI, E. Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review. In KIDNEY AND DIALYSIS. DEC 2024, vol. 4, no. 4, p. 184-202. Dostupné na: https://doi.org/10.3390/kidneydial4040016. GUPTA, R. - UMEH, C. - MOHTA, T. - VAIDYA, A. - WOLFSON, A. - NATTIV, J. - BHATIA, H. - KAUR, G. - DHAWAN, R. - DARJI, P. - EGHRERINIOVO, B. - SANWO, E. - HOTWANI, P. - MAHDAVIAN, P. - KUMAR, S. - TIWARI, B. Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials. In IJC HEART & VASCULATURE. DEC 2024, vol. 55. Dostupné na: https://doi.org/10.1016/j.ijcha.2024.101539. YUAN, X. - PAN, L. - ZHANG, C. - ZHU, Q.L. - HUANG, Z.X. - QIN, Y. - ZHANG, G.P. - FENG, Z.M. - YANG, C.X. - HOU, N. Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway. In FRONTIERS IN PHARMACOLOGY. NOV 27 2024, vol. 15. Dostupné na: https://doi.org/10.3389/fphar.2024.1499542. YERRA, V.G. - CONNELLY, K.A. Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies. In PHYSIOLOGY. ISSN 1548-9213, NOV 18 2024, vol. 39, no. 6, p. 412-434. Dostupné na: https://doi.org/10.1152/physiol.00008.2024. FIBBI, G. - SATO, R. - VATIC, M. - GENREITH, F.P. - VON HAEHLING, S. Pharmacological management of heart failure: a patient-centred approach. In EXPERT OPINION ON PHARMACOTHERAPY. ISSN 1465-6566, NOV 1 2024, vol. 25, no. 16, p. 2151-2165. Dostupné na: https://doi.org/10.1080/14656566.2024.2418414. LI, W.D. - SHEN, X.Y. - ZHANG, M.Q. - TAN, W.T. - JIANG, X.L. - WEN, H.F. - SHEN, Y. Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients. In MEDICINE. ISSN 0025-7974, NOV 8 2024, vol. 103, no. 45. Dostupné na: https://doi.org/10.1097/MD.0000000000040409. SELVARAJ, S. - PATEL, S. - SAUER, A.J. - MCGARRAH, R.W. - JONES, P. - KWEE, L.C. - WINDSOR, S.L. - ILKAYEVA, O. - MUEHLBAUER, M.J. - NEWGARD, C.B. - BORLAUG, B.A. - KITZMAN, D.W. - SHAH, S.J. - MARGULIES, K.B. - HUSAIN, M. - INZUCCHI, S.E. - MCGUIRE, D.K. - LANFEAR, D.E. - JAVAHERI, A. - UMPIERREZ, G. - MENTZ, R.J. - SHARMA, K. - KOSIBOROD, M.N. - SHAH, S.H. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. In CIRCULATION-HEART FAILURE. ISSN 1941-3289, NOV 2024, vol. 17, no. 11. Dostupné na: https://doi.org/10.1161/CIRCHEARTFAILURE.124.011980. BHANDARI, M. - PRADHAN, A. - VISHWAKARMA, P. - SINGH, A. - SETHI, R. Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici. In WORLD JOURNAL OF CARDIOLOGY. ISSN 1949-8462, OCT 26 2024, vol. 16, no. 10. Dostupné na: https://doi.org/10.4330/wjc.v16.i10.550. TIWARI, K. - DEORA, S. - CHOUDHARY, R. - KAUSHIK, A. - DWIVEDI, P. - SINGH, S. - AMBWANI, S. - MIDHA, N. - SHUKLA, R. - SANKANAGOUDAR, S. - SHAMIM, M.A. - TIWARI, V.K. - YADAV, I. - DODIYA, R. - VARTHYA, S.B. Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol. In BMJ OPEN. ISSN 2044-6055, OCT 18 2024, vol. 14, no. 10. Dostupné na: https://doi.org/10.1136/bmjopen-2024-089562. NG, Y.H. - KOAY, Y.C. - MARQUES, F.Z. - KAYE, D.M. - O'SULLIVAN, J.F. Leveraging metabolism for better outcomes in heart failure. In CARDIOVASCULAR RESEARCH. ISSN 0008-6363, OCT 7 2024, vol. 120, no. 15, p. 1835-1850. Dostupné na: https://doi.org/10.1093/cvr/cvae216. HAHN, V.S. - SELVARAJ, S. - SHARMA, K. - SHAH, S.H. Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure. In JACC-BASIC TO TRANSLATIONAL SCIENCE. ISSN 2452-302X, SEP 2024, vol. 9, no. 9, p. 1144-1158. Dostupné na: https://doi.org/10.1016/j.jacbts.2024.04.008. FU, K. - YANG, Z.H. - WANG, N. - DONG, Y.R. - WANG, Z.Y. - CHEN, W.Q. - LU, H.X. Recurrence of left ventricular systolic dysfunction and its risk factors in heart failure with improved ejection fraction patients receiving guideline-directed medical therapy: A trajectory analysis based on echocardiography. In INTERNATIONAL JOURNAL OF CARDIOLOGY. ISSN 0167-5273, NOV 15 2024, vol. 415. Dostupné na: https://doi.org/10.1016/j.ijcard.2024.132370. IPEK, R. - HOLLAND, J. - CRAMER, M. - RIDER, O. CMR to characterize myocardial structure and function in heart failure with preserved left ventricular ejection fraction. In EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING. ISSN 2047-2404, SEP 6 2024, vol. 25, no. 11, SI, p. 1491-1504. Dostupné na: https://doi.org/10.1093/ehjci/jeae224. LAZAREVA, L. - SHUBROOK, J.H. - DHOND, M. Comprehensive review of the heart failure management guidelines presented by the American College of Cardiology and the current supporting evidence. In JOURNAL OF OSTEOPATHIC MEDICINE. DEC 20 2024, vol. 125, no. 1, p. 1-8. Dostupné na: https://doi.org/10.1515/jom-2024-0071. HARADA, T. - TADA, A. - BORLAUG, B.A. Imaging and mechanisms of heart failure with preserved ejection fraction: a state-of-the-art review. In EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING. ISSN 2047-2404, JUL 10 2024, vol. 25, no. 11, SI, p. 1475-1490. Dostupné na: https://doi.org/10.1093/ehjci/jeae152. BORNSTEIN, M.R. - TIAN, R. - ARANY, Z. Human cardiac metabolism. In CELL METABOLISM. ISSN 1550-4131, JUL 2 2024, vol. 36, no. 7, p. 1456-1481. Dostupné na: https://doi.org/10.1016/j.cmet.2024.06.003. IONICA, L.N. - LINTA, A.V. - BATRIN, A.D. - HâNCU, I.M. - LOLESCU, B.M. - DANILA, M.D. - PETRESCU, L. - MOZOS, I.M. - STURZA, A. - MUNTEAN, D.M. The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview. In INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. ISSN 1661-6596, JUL 2024, vol. 25, no. 14. Dostupné na: https://doi.org/10.3390/ijms25147711. SELVARAJ, S. - PATEL, S. - SAUER, A.J. - MCGARRAH, R.W. - JONES, P. - KWEE, L.C. - WINDSOR, S.L. - ILKAYEVA, O. - MUEHLBAUER, M.J. - NEWGARD, C.B. - BORLAUG, B.A. - KITZMAN, D.W. - SHAH, S.J. - SHAH, S.H. - KOSIBOROD, M.N. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction. In JACC-HEART FAILURE. ISSN 2213-1779, JUN 2024, vol. 12, no. 6, p. 999-1011. Dostupné na: https://doi.org/10.1016/j.jchf.2024.02.018. COWLEY, A.C. - DATTANI, A. - BRADY, E.M. - MCCANN, G.P. - GULSIN, G.S. Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part II. In BRITISH JOURNAL OF DIABETES. ISSN 2397-6233, JUN 2024, vol. 24, no. 1, p. 24-29. Dostupné na: https://doi.org/10.15277/bjd.2024.442. TSURUTA, H. - YAMAHARA, K. - YASUDA-YAMAHARA, M. - KUME, S. Emerging Pathophysiological Roles of Ketone Bodies. In PHYSIOLOGY. ISSN 1548-9213, MAY 23 2024, vol. 39, no. 3, p. 167-177. Dostupné na: https://doi.org/10.1152/physiol.00031.2023. DABOUR, M.S. - GEORGE, M.Y. - DANIEL, M.R. - BLAES, A.H. - ZORDOKY, B.N. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors. In JACC: CARDIOONCOLOGY. ISSN 2666-0873, APR 2024, vol. 6, no. 2, p. 159-182. Dostupné na: https://doi.org/10.1016/j.jaccao.2024.01.007. VON HAEHLING, S. - ASSMUS, B. - BEKFANI, T. - DWORATZEK, E. - EDELMANN, F. - HASHEMI, D. - HELLENKAMP, K. - KEMPF, T. - RAAKE, P. - SCHüTT, K.A. - WACHTER, R. - SCHULZE, P.C. - HASENFUSS, G. - BöHM, M. - BAUERSACHS, J. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. In CLINICAL RESEARCH IN CARDIOLOGY. ISSN 1861-0684, SEP 2024, vol. 113, no. 9, SI, p. 1287-1305. Dostupné na: https://doi.org/10.1007/s00392-024-02396-4. GAO, M.C. - BHATIA, K. - KAPOOR, A. - BADIMON, J. - PINNEY, S.P. - MANCINI, D.M. - SANTOS-GALLEGO, C.G. - LALA, A. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure. In JAMA NETWORK OPEN. ISSN 2574-3805, APR 4 2024, vol. 7, no. 4. Dostupné na: https://doi.org/10.1001/jamanetworkopen.2024.5135. CERSOSIMO, A. - SALERNO, N. - SABATINO, J. - SCATTEIA, A. - BISACCIA, G. - DE ROSA, S. - DELLEGROTTAGLIE, S. - BUCCIARELLI-DUCCI, C. - TORELLA, D. - LEO, I. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance. In CARDIOVASCULAR DIABETOLOGY. MAR 11 2024, vol. 23, no. 1. Dostupné na: https://doi.org/10.1186/s12933-024-02181-7. TRIPOSKIADIS, F. - XANTHOPOULOS, A. - DRAKOS, S.G. - BOUDOULAS, K.D. - BRIASOULIS, A. - SKOULARIGIS, J. - TSIOUFIS, K. - BOUDOULAS, H. - STARLING, R.C. Back to the basics: The need for an etiological classification of chronic heart failure. In CURRENT PROBLEMS IN CARDIOLOGY. ISSN 0146-2806, APR 2024, vol. 49, no. 4. Dostupné na: https://doi.org/10.1016/j.cpcardiol.2024.102460. OSTROMINSKI, J.W. - VADUGANATHAN, M. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction. In AMERICAN JOURNAL OF MEDICINE. ISSN 0002-9343, FEB 2024, vol. 137, no. 2, p. S9-S24. Dostupné na: https://doi.org/10.1016/j.amjmed.2023.04.035. NILSSON, C.N. - ERSBOLL, M.K. - GUSTAFSSON, F. Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients. In CARDIAC FAILURE REVIEW. ISSN 2057-7540, 2024, vol. 10. Dostupné na: https://doi.org/10.15420/cfr.2023.25. ARVIDSSON, P.M. - BERG, J. - CARLSSON, M. - ARHEDEN, H. Noninvasive Pressure-Volume Loops Predict Major Adverse Cardiac Events in Heart Failure With Reduced Ejection Fraction. In JACC: ADVANCES. 2024, vol. 3, no. 6. Dostupné na: https://doi.org/10.1016/j.jacadv.2024.100946. KUWAHARA, K. Therapeutic Mechanisms of SGLT2 Inhibitor in HfpEF. In SHINZO. 2024, vol. 56, no. 2, p. 170-177. Dostupné na: https://doi.org/10.11281/shinzo.56.170. FORELLI, N. - EATON, D. - PATEL, J. - BOWMAN, C.E. - KAWAKAMI, R. - KUZNETSOV, I.A. - LI, K. - BRADY, C. - BEDI, K. - YANG, Y. - KOYA, K. - MEGILL, E. - KANTER, D.S. - SMITH, L.G. - BOWMAN, G.R. - SNYDER, N. - EDWARDS, J. - MARGULIES, K. - ARANY, Z. SGLT2 inhibitors activate pantothenate kinase in the human heart. In bioRxiv, 2024, https://doi.org/10.1101/2024.07.26.605401. MOLDOBAEVA, M.S. – OMURZAKOVA, U.K. Effectiveness of Empagliflozin in Treatment of Patients with Type 2 Diabetes Mellitus Combined with Heart Failure Depending of ATP Level. In EUROASIAN HEALTH JOURNAL. 2024, no. 2, p. 53-63. Dostupné na: https://doi.org/10.54890/1694-8882-2024-2-53. BARISON, A. - TIMOTEO, A.T. - LIGA, R. - BORODZICZ-JAZDZYK, S. - EL MESSAOUDI, S. - LUONG, C. - MANDOLI, G.E. - MOSCATELLI, S. - RAMKISOENSING, A.A. - MOHAREM-ELGAMAL, S. - PONTONE, G. - NEGLIA, D. Cardiovascular imaging research and innovation in 2023. In EUROPEAN HEART JOURNAL - IMAGING METHODS AND PRACTICE. 2024, vol. 2, no. 1. Dostupné na: https://doi.org/10.1093/ehjimp/qyae029. SUN, S. - LAI, C.J. - HUANG, C.C. - WANG, R.L. - FU, G.S. - SHANG, M. Harnessing integrated bioinformatics to identify new diagnostic and therapeutic strategies for heart failure. In BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. ISSN 0925-4439, OCT 2025, vol. 1871, no. 7, art. no. 167909. Dostupné na: https://doi.org/10.1016/j.bbadis.2025.167909. MERICSKAY, M. - ZUURBIER, C.J. - HEATHER, L.C. - KARLSTAEDT, A. - INSERTE, J. - BERTRAND, L. - KARARIGAS, G. - RUIZ-MEANA, M. - MAACK, C. - SCHIATTARELLA, G.G. Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets. In NATURE REVIEWS CARDIOLOGY. ISSN 1759-5002, 2025 JUN 22 2025. Dostupné na: https://doi.org/10.1038/s41569-025-01166-7. STüDEMANN, S. - ENGELI, S. Are GLP-1 receptor agonists and SGLT2 inhibitors also suitable for older people?. In DIABETOLOGIE UND STOFFWECHSEL. ISSN 1861-9002, JUN 2025, vol. 20, no. 03, p. 211-229. Dostupné na: https://doi.org/10.1055/a-2582-5787. MARWICK, T.H. - HALABI, A. - SOH, C.H. - CURTIN, A. - SHERRIF, A.G. - AZAD, A. - WRIGHT, L. Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial. In CARDIOVASCULAR DIABETOLOGY. MAY 30 2025, vol. 24, no. 1, art. no. 232. Dostupné na: https://doi.org/10.1186/s12933-025-02796-4. CINTI, F. - LABORANTE, R. - CAPPANNOLI, L. - MORCIANO, C. - GUGLIANDOLO, S. - PONTECORVI, A. - BURZOTTA, F. - DONNIACUO, M. - CAPPETTA, D. - PATTI, G. - GIACCARI, A. - D'AMARIO, D. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?. In CARDIOVASCULAR DIABETOLOGY. MAY 14 2025, vol. 24, no. 1, art. no. 208. Dostupné na: https://doi.org/10.1186/s12933-025-02767-9. DAKHILI, S.A.T. - YANG, K.Y. - STENLUND, M.J. - USSHER, J.R. The multifaceted roles of ketones in physiology. In EXPERIMENTAL PHYSIOLOGY. ISSN 0958-0670, 2025 MAY 11 2025. Dostupné na: https://doi.org/10.1113/EP092243. GOJE, I.D. - GOJE, G.I. - ORDODI, V.L. - CIOBOTARU, V.G. - IVAN, V.S. - BUZAS, R. - TUNEA, O. - BOJIN, F. - LIGHEZAN, D.F. Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. In PHARMACEUTICALS. MAY 3 2025, vol. 18, no. 5, art. no. 681. Dostupné na: https://doi.org/10.3390/ph18050681. CHAN, J.S.F. - SHAFAATI, T. - USSHER, J.R. Cardiac substrate metabolism in type 2 diabetes. In BIOCHEMICAL JOURNAL. ISSN 0264-6021, MAY 2025, vol. 482, no. 10, p. 499-518. Dostupné na: https://doi.org/10.1042/BCJ20240189. LIU, X.H. - ZHAO, H.Q. - LIU, S.S. - WEN, S. - FAN, W.J. - XIE, Q. - CUI, B. - ZHOU, L. - PENG, J.Q. - PAN, H.W. - ZHENG, Z.F. - ZHANG, Q.H. Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice. In FRONTIERS IN CARDIOVASCULAR MEDICINE. ISSN 2297-055X, APR 29 2025, vol. 12, art. no. 1533820. Dostupné na: https://doi.org/10.3389/fcvm.2025.1533820. DE SOUZA, M.D. - DEFANTE, M.L.R. - MORAIS, B.A.D.D. - MUNIZ, J. - MENDES, B.X. - MARTINS, O.C. - PRIZAO, V.M. - SILVA, M.M.F. Effects of SGLT2 inhibitors on health-related quality of life and functional capacity in patients with heart failure with and without diabetes: a meta-analysis of randomized controlled trials. In INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. ISSN 2210-7703, JUN 2025, vol. 47, no. 3, p. 654-665. Dostupné na: https://doi.org/10.1007/s11096-025-01908-0. HU, Y.C. - CHEN, X.Y. - ZHAO, Q.M. - LI, G.H. - ZHANG, H. - MA, Z. - YU, H. - ZENG, Q.C. - ZHANG, H.P. - XU, D.L. Berberine improves cardiac insufficiency through AMPK/PGC-1α signaling-mediated mitochondrial homeostasis and apoptosis in HFpEF mice. In INTERNATIONAL IMMUNOPHARMACOLOGY. ISSN 1567-5769, MAY 16 2025, vol. 155, art. no. 114613. Dostupné na: https://doi.org/10.1016/j.intimp.2025.114613. GONçALVES, A. - ALVES, I.N. - MENDES, C. - MIRANDA, D. - CONCEIçAO, G. - ALMEIDA-COELHO, J. - MARTINS, D. - MIRANDA, I. - RODRIGUES, A. - SILVA, C. - OLIVEIRA, S.M. - SERENO, J. - FERREIRA, M.J. - DISCHINGER, U. - GIRAO, H. - LEITE-MOREIRA, A.F. - SEQUEIRA, V. - FALCAO-PIRES, I. Ketogenic diet and ketone salts differentially improve cardiometabolic complications in an HFpEF rat model. In JOURNAL OF PHYSIOLOGY-LONDON. ISSN 0022-3751, 2025 APR 3 2025. Dostupné na: https://doi.org/10.1113/JP288229. WENG, J.F. - DONG, W. - LIAO, R.C. - ZHENG, Y.F. - FANG, X. - YOU, J.X. - WANG, Z.C. - ZUO, Y.B. - CHEN, X.Y. - PENG, X.P. High triglyceride-to-high-density lipoprotein cholesterol ratio predicts poor prognosis in new-onset heart failure: a retrospective study. In BMC CARDIOVASCULAR DISORDERS. ISSN 1471-2261, APR 2 2025, vol. 25, no. 1, art. no. 251. Dostupné na: https://doi.org/10.1186/s12872-025-04706-8. DE LUCA, G.D. - PALAMA, Z. - LONGO, S. - BARBA, F. - ROBLES, A.G. - NESTI, M. - SCARA, A. - COLUCCIA, G. - COLOPI, M. - DE LUCA, G.D. - MINARDI, S. - FUSCO, L. - PALMISANO, P. - ACCOGLI, M. - SCIARRA, L. - ROMANO, S. Effect of Dapagliflozin on Ventricular Arrhythmic Events in Heart Failure Patients With an Implantable Cardioverter Defibrillator. In CARDIOLOGY RESEARCH. ISSN 1923-2829, APR 2025, vol. 16, no. 2, p. 140-152. Dostupné na: https://doi.org/10.14740/cr2018. GHAZAL, R. - WANG, M. - LIU, D. - TSCHUMPERLIN, D.J. - PEREIRA, N.L. Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure. In CIRCULATION RESEARCH. ISSN 0009-7330, MAR 28 2025, vol. 136, no. 7, p. 773-802. Dostupné na: https://doi.org/10.1161/CIRCRESAHA.124.325402. FENG, Q. - WU, M.Q. - MAI, Z.Z. Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes. In FRONTIERS IN CARDIOVASCULAR MEDICINE. ISSN 2297-055X, MAR 20 2025, vol. 12, art. no. 1482918. Dostupné na: https://doi.org/10.3389/fcvm.2025.1482918. WANG, Y.F. - QIN, Y.H. - ZHANG, J. - WU, A.H. - QIN, X.H. - DU, L. - ZHANG, H.B. - GUO, X.X. - ZHANG, S.Y. Sodium-Glucose Cotransporter-2 Inhibitors and Diabetic-Ketoacidosis in T2DM Patients: An Updated Meta-Analysis and a Mendelian Randomization Analysis. In CLINICAL PHARMACOLOGY & THERAPEUTICS. ISSN 0009-9236, JUN 2025, vol. 117, no. 6, p. 1661-1669. Dostupné na: https://doi.org/10.1002/cpt.3615. ANGERMANN, C.E. - SEHNER, S. - GERHARDT, L.M.S. - SANTOS-GALLEGO, C.G. - REQUENA-IBANEZ, J.A. - ZELLER, T. - MAACK, C. - SANZ, J. - FRANTZ, S. - ERTL, G. - BADIMON, J.J. Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial. In EUROPEAN HEART JOURNAL. ISSN 0195-668X, APR 21 2025, vol. 46, no. 16, p. 1507-1523. Dostupné na: https://doi.org/10.1093/eurheartj/ehae917. LAKHAL-LITTLETON, S. Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?. In EUROPEAN HEART JOURNAL. ISSN 0195-668X, APR 21 2025, vol. 46, no. 16, p. 1524-1527. Dostupné na: https://doi.org/10.1093/eurheartj/ehae798. TAN, W.P. - WANG, Y.J. - CHENG, S.Y. - LIU, Z.H. - XIE, M.J. - SONG, L.P. - QIU, Q.F. - WANG, X.F. - LI, Z.Y. - LIU, T.Y. - GUO, F.D. - WANG, J. - ZHOU, X.Y. AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis. In JOURNAL OF ADVANCED RESEARCH. ISSN 2090-1232, FEB 2025, vol. 68, p. 299-315. Dostupné na: https://doi.org/10.1016/j.jare.2024.02.015. HOPKINS, S. - BAQAI, F. - GAJAGOWNI, S. - HICKEY, G. Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class. In JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. ISSN 1074-2484, 2025, vol. 30, art. no. 10742484251323428. Dostupné na: https://doi.org/10.1177/10742484251323428. Category ADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted) Category of document (from 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Type of document článok Year 2023 Registered in WOS Registered in SCOPUS Registered in CCC DOI 10.1161/CIRCULATIONAHA.122.062021 
article
File name Access Size Downloaded Type License Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin.pdf available 1.3 MB 20 Publisher's version rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2023 2022 37.8 Q1 7.8 Q1
Number of the records: 1